Company Revenue Reports

The company said its established markets are nearing pre-pandemic sales levels, with ongoing monthly improvement.

The company accelerated its growth to 32% in FY 4Q20 but couldn't completely offset pandemic-related declines for the year.

The company declined in the mid-single digits due to COVID-related headwinds and inventory stocking declines in its orthobiologics franchise.

The company grew 31% in the first quarter of 2021, hitting double-digit growth even with ten-year-old products.

The company declined in the mid-teens for 1Q21 but hopes to return to product revenue growth above 2019-levels by the end of the year.

The company grew 45% in 1Q21 despite surgical volume pressure in January and February as ATEC continues to drive conversion and uptake.

The company grew in the mid-single-digits for the first quarter, as recovery in global markets offset some choppiness in the U.S.

The company's MACI business grew nearly +20% in the first quarter of 2021 as Vericel continues to broaden its surgeon user base.

The company grew in the low single-digits for 1Q21, with important contributions from ROSA and its Signature ONE shoulder planner.

The company's spine business grew over 20% in the first quarter, driven by robotic pull-through, new products and competitive recruiting.